Skip to main content

Table 2 Patient characteristics

From: The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting

Variable Non-BRCA1ness BRCA1ness p value
(N = 61) (N = 55)
Treatment
 Control 27 (44.3) 17 (30.9) 0.198a
 Veliparib/carboplatin 34 (55.7) 38 (69.1
Hormone receptor status
 HR+ 48 (78.7) 8 (14.5) <0.05a
 TN 13 (21.3) 47 (85.5)
Tumor size (cm)
 0–1 0 (0) 0 (0) 0.496a
 >1–2 0 (0) 1 (1.8)
 >2–5 40 (65.6) 31 (56.4)
 >5 19 (31.4) 22 (40.0)
  1. Data presented as number (%)
  2. HR hormone receptor status, TN triple-negative
  3. aPearson’s chi-squared test